Learning and innovation in the Indian pharmaceutical industry: the role of IPR and other policy interventions
DOI:
https://doi.org/10.3395/reciis.v2i2.862Keywords:
Technological learning and innovation, Indian pharmaceutical industryAbstract
Through the decades of 1970s and 1980s, the Indian pharmaceutical industry (IPR) reached new heights of process capabilities. At the present juncture, however, the industry is at a watershed, trying to cope with the challenges of globalisation and reforms. It is going through a turbulent phase of adjustment driven by the emerging international economic order of the WTO, especially the TRIPS agreement establishing a new IPR environment. The aim of this paper is to explore the trajectory of learning and innovation in the IPR as it evolved through the various phases of government policy environment and IPR regimes. We conclude that although India has reached impressive heights of technological maturity in pharmaceuticals, it is yet to arrive at the global frontiers of cutting edge drug discovery research. This can only be achieved through sustained technological effort and continued R&D.Downloads
Published
How to Cite
Issue
Section
License
Author’s rights: The author retains unrestricted rights over his work.
Rights to reuse: Reciis adopts the Creative Commons License, CC BY-NC non-commercial attribution according to the Policy on Open Access to Knowledge by Oswaldo Cruz Foundation. With this license, access, download, copy, print, share, reuse, and distribution of articles is allowed, provided that it is for non-commercial use and with source citation, granting proper authorship credits and reference to Reciis. In such cases, no permission is required from the authors or editors.
Rights of authors’s deposit / self-archiving: The authors are encouraged to deposit the published version, along with the link of their article in Reciis, in institutional repositories.